CEO Robert Goldfarb is about to retire on March 31st and will be replaced by David Poppe. Sequoia shares plunged because of Valeant Pharmaceuticals Inc. stake.
Goldman Sachs Group Inc is facing tough time in selling $2.8 billion of debt in the wake of ongoing drug pricing controversy in the pharmaceutical industry.
Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.
Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.
Prominent investor shareholder advisory firm ISS called on Allergan Inc to give its shareholders a chance to vote on any large, buyout-blocking acquisitions and said the company's board faced a credibility problem, according to a report seen by Reuters.
Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company.
Solta Medical Inc. has put up the company for sale amid falling profits and pressure from activist investor Voce Capital Management LLC. California-based Valeant Pharmaceuticals International will buy Solta Medical for $236 million in cash.
Subscribe to VCpost newsletter
- Lance Armstrong's Next Ventures Raises $24.5 Million Of Expected $75 Million Fundraise
- Implied SPDR S&P MIDCAP 400 ETF Analyst Target Price: $389
- What This Centi-Billionaire Fashion Magnate Can Teach You About Investing
- ADP vs. Paychex: Comparing Key Metrics For The Two Largest Payroll Processing Companies
- After Energy Sector Earnings Plunge In Q1, Hopes Rise For Improved Q2 Performance
- Are Strong Jobs Really Bad For Stocks?
- 4 Price Charts You Should See: Bank Stocks Are Showing Relative Weakness
- Citigroup's $21.5-Billion Capital Return Plan For 2019 Is Slightly Lower Than Its 2018 Plan